Chronic kidney disease in Korean patients with lupus nephritis: over a 35-year period at a single center.

Clin Rheumatol

Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea.

Published: June 2022

AI Article Synopsis

  • Chronic kidney disease (CKD) significantly impacts health outcomes in patients with lupus nephritis (LN), yet there’s limited research on its development within this group.
  • A study analyzed 401 LN patients over 35 years to identify factors predicting CKD risk, finding that 15.5% developed CKD within 10 years post-diagnosis.
  • Key predictors for CKD included delayed-onset LN, acute renal dysfunction at diagnosis, and insufficient treatment response at 6 or 12 months, rather than initial severity of kidney damage or protein levels.

Article Abstract

Introduction: Chronic kidney disease (CKD) is a major risk factor for overall morbidity and mortality even in lupus nephritis (LN) patients. However, less attention has been paid to the development of CKD in patients with LN. The objective of this study was to identify predictors for CKD with 35-year experience depending on newly revised guidelines for patients with LN.

Methods: We conducted a retrospective cohort study for 401 patients who visited Seoul St. Mary's Hospital between January 1985 and December 2019. We analyzed clinical and laboratory indices, treatment response, the final renal function, and biopsy findings. The timing and cumulative risk of developing CKD were identified by Kaplan-Meier methods. Independent risk factors for developing CKD were examined by Cox proportional hazard regression analyses.

Results: The median follow-up time after the diagnosis of LN was 131 months. CKD occurred in 15.5% of patients within 10 years after the diagnosis of LN. The development of CKD was associated with delayed-onset LN, acute renal dysfunction at onset of LN, and failure to reach complete response (CR) at 6 or 12 months rather than histopathological findings or the severity of proteinuria at onset of LN. Cumulative incidence of progression to CKD was significantly higher in patients with the three predictors mentioned above.

Conclusion: Ten-year cumulative incidence of CKD was about 15%. Our results showed that delayed-onset LN, acute renal dysfunction at the onset of LN, and inadequate treatment response assessed at 6 or 12 months after treatment were predictors for the development of CKD in LN. Key Points • CKD is a major risk factor for overall morbidity and mortality in LN patients. • Ten-year cumulative incidence of CKD was about 15% • Delayed-onset LN, acute renal dysfunction at the onset of LN, and inadequate treatment response assessed at 6 or 12 months after treatment were predictors for the development of CKD in LN.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-021-06030-wDOI Listing

Publication Analysis

Top Keywords

development ckd
16
ckd
13
treatment response
12
delayed-onset acute
12
acute renal
12
renal dysfunction
12
dysfunction onset
12
cumulative incidence
12
chronic kidney
8
kidney disease
8

Similar Publications

Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.

Front Endocrinol (Lausanne)

January 2025

Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, Liaoning, China.

Objective: The impact of lipid-lowering medications on chronic kidney disease (CKD) remains a subject of debate. This Mendelian randomization (MR) study aims to elucidate the potential effects of lipid-lowering drug targets on CKD development.

Methods: We extracted 11 genetic variants encoding targets of lipid-lowering drugs from published genome-wide association study (GWAS) summary statistics, encompassing LDLR, HMGCR, PCSK9, NPC1L1, APOB, ABCG5/ABCG8, LPL, APOC3, ANGPTL3, and PPARA.

View Article and Find Full Text PDF

Daprodustat, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor is approved in the United States for the treatment of anemia due to chronic kidney disease (CKD) in adults receiving dialysis for at least 4 months. Pharmacodynamic dose-hemoglobin (Dose-Hgb) models were developed as daprodustat progressed through development. To support global phase III development, a dose-titration algorithm, guided by simulations from the initial Dose-Hgb model based on phase II clinical data, was implemented.

View Article and Find Full Text PDF

Case-control study on long-term kidney outcomes in very low birth weight infants: impact of growth restriction and maternal preeclampsia.

J Pediatr (Rio J)

January 2025

Universidade de Caxias do Sul, Programa de Pós-Graduação em Ciências da Saúde, Caxias do Sul, RS, Brazil; Universidade de Caxias do Sul, Área do Conhecimento de Ciências da Vida, Caxias do Sul, RS, Brazil; Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil.

Objective: To identify factors, particularly neonatal acute kidney injury, associated with an increased risk of developing chronic kidney disease (CKD) within the first 10 years of life in children with a history of prematurity and very low birth weight (VLBW).

Methods: This nested case-control study was conducted on VLBW infants (> 500 g and < 1.500 g) born between 2012 and 2022.

View Article and Find Full Text PDF

Background: Patients with kidney disease are at high risk for adverse outcomes after coronavirus disease 2019 (COVID-19) despite vaccination. Because patients with advanced chronic kidney disease (CKD) and kidney failure were excluded from registrational trials, the impact of the protease inhibitor nirmatrelvir-ritonavir in patients with kidney disease is unknown.

Methods: This was a cohort study evaluating adverse outcomes in patients with kidney disease who developed COVID-19.

View Article and Find Full Text PDF

Purpose: Social determinants of health have been related with kidney diseases and their outcomes. Financial toxicity (FT) refers to the negative impact of health care costs on clinical conditions. This scoping review aimed to evaluate the literature linking FT with renal diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!